Kornimate/medical-research-clean huggingface dataset:
investigating the correlations between dysphagia symptoms and swallowing muscle groups by hrpm-i

Conditions: Swallowing Contraction Strength

Summary: investigating the correlation between the dysphagia symptoms and swallowing muscle groups by high resolution pharyngeal manometry with impedance

backgrounds: some patients would experience dysphagia symptoms before the elective surgery. these patients usually do not have a history of head and neck surgery or cerebrovascular diseases. they are common causes of dysphagia. the anesthetics and airway manipulation can exacerbate dysphagia. however, research is limited on the specific weak muscle groups in patients with dysphagia symptoms, as well as on the existence of associated malnutrition. aims: the eating assessment tool (eat-10) questionnaire will be used to assess dysphagia symptoms. a score of ≥4 on the eat-10 indicates the presence of dysphagia symptoms, while a score of \<4 indicates the absence. this study aims to (1) investigate which specific muscle groups are particularly weak in patients with dysphagia symptoms (eat-10≥4); (2) to examine whether patients with dysphagia symptoms (eat-10≥4) have poorer nutritional status than patients without dysphagia symptoms (eat-10\<4). methods: this is a cross-sectional study. the investigators will recruit patients undergoing elective orthopedic surgery on the lower extremities, with the age range of 18 to 90 years. on the day of admission, patients will be examined by the eat-10 questionnaire for dysphagia symptoms. high-resolution pharyngeal manometry with impedance will be conducted to measure the functional of swallowing muscles. additionally, patients will be given the mini nutritional assessment (mna) questionnaire (a total score of 30 points). the higher scores indicate the better nutritional status. the albumin level will also be collected. the bioelectrical impedance analysis will be used to measure the patients' body composition, specifically skeletal muscle mass.

Eligibility criteria:
inclusion criteria: * age from 20 to 80 years exclusion criteria: * bleeding tendency * pregnancy * heart failure * chronic kidney disease
personalized nutrition counseling and nutritional status of esophageal cancer and hnscc patients undergoing ccrt

Conditions: Esophageal Cancer; Personalized Nutrition

Summary: the purpose of the study is to improve the nutritional status of esophageal cancer patients undergoing concurrent chemoradiotherapy by the personalized nutrition counseling.dietitians consult with participants which invited to be the experimental group and follow up weekly through communication software (line) or telephone remote methods. dietitians provide the dietary advice base on the guidance of the cancer diet principles, and give on assessment and diet adjustments. at the same time, under the same condition of nutritional supplements in both the experimental group and the control group, the investigators explore the changes in the quality of life and nutritional status of the subjects by evaluating with the nutrition index (pg-sga) and quality of life (eortc qlq-c30 questionnaire taiwan version) questionnaire evaluation and recode the basic physical data, including body weight, grip strength, body muscle fat composition. therefore, investigators conducted this study to appoint dietitian to arrange personalized nutrition consultation for esophageal cancer patients to improve the nutritional status of these patients.

approximately 60-85% of esophageal cancer patients present with malnutrition at diagnosis (1). malnutrition, defined as body weight loss of more than 10% over the previous 6 months is associated with treatment response and survival (2). around 38% of esophageal cancer patients are managed with curative intent in the form of neoadjuvant chemotherapy or chemoradiotherapy followed by esophagectomy (3). individuals are at increased risk of malnutrition arising from disease related symptoms and neoadjuvant treatment. nutritional status serves as an important risk factor for major complications after operation (4) therefore, assessment of nutritional status should be undertaken for all esophageal cancer patients, especially for those who are planned to receive esophagectomy (5). the nutritional assessment includes hand grip for muscle mass (6), body composition for lean body mass and sarcopenia (7), body mass index- body weight loss grade (bmi-bwl grade) for generalized nutrition status (8). these tools are needed to be integrated and individualized to esophageal cancer patients to improve outcome. therefore, investigators conducted this trial to appoint dietitian to arrange personalized nutrition consultation for esophageal cancer patients to improve the nutritional status of these patients.

Eligibility criteria:
inclusion criteria: 1. pathologically and ct confirmed esophageal cancer or head and neck cancer 2. ccrt therapy 3. ecog performance status grade≦2 4. agree to participate the trial 5. over 18 years 6. no pregnant exclusion criteria: 1. have two or more cancers 2. gastrointestinal tract cannot function 3. nyha class 4 4. abnormal liver and kidney function 5. abnormal bone marrow hematopoiesis

Keywords: personalized nutrition esophageal cancer concurrent chemoradiotherapy
evaluation of safety and efficacy of ctx001 in pediatric participants with transfusion-dependent β-thalassemia (tdt)

Conditions: Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn; Hematologic Diseases; Hemoglobinopathies

Summary: this is a single-dose, open-label study in pediatric participants with tdt. the study will evaluate the safety and efficacy of autologous crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells (hhspcs) (ctx001).


Eligibility criteria:
key inclusion criteria: * diagnosis of tdt as defined by: * documented homozygous or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin e (hbe). participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning * history of at least 100 ml/kilograms (kg)/year of packed rbc transfusions in the prior 24 months before signing of consent (or the last rescreening for patients going through repeat screening) or, for participants initiating transfusion therapy \<24 months before signing of consent, requirement for packed rbc transfusion at least every 3 to 4 weeks for ≥6 months * eligible for autologous stem cell transplant as per investigator's judgment. key exclusion criteria: * a willing and healthy 10/10 human leukocyte antigen (hla)-matched related donor is available per investigator's judgement * prior hematopoietic stem cell transplant (hsct) * participants with associated α-thalassemia and \>1 alpha deletion, or alpha multiplications * participants with sickle cell β-thalassemia variant * clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator other protocol defined inclusion/exclusion criteria may apply.
thyroidectomy using ultrasonic dissector: is superior laryngeal nerve really safe ?

Conditions: Goiter

Summary: new devices and techniques are coming into use everyday. ultrasonic dissectors (uds) are such new devices which is a practical alternative to the usage of scalpel and sutures. ud's cause overheating of neighboring tissues in an area of 1 to 3 millimeters. due to the generated heat uds might cause nerve injury. the investigators would like to see if usage of uds during thyroidectomy poses a risk for superior laryngeal nerve injury compared to conventional thyroidectomy.

we see new advances in the practice of surgery nearly everyday. new techniques and devices became available and even newer ones are under developement. ultrasonic dissectors (uds) which are primarily developed for laparoscopic surgery found widespread use in thyroid surgery. uds while closing the nearby vessels cause overheating of neighboring tissues in a 1-3 mm. area. due to the generated heat uds might cause nerve injury. we would like to see if usage of uds during thyroidectomy poses a risk for superior laryngeal nerve injury compared to conventional thyroidectomy where vessels are first sealed with sutures then cut. to this end patients in both conventional and ultrasonic dissector thyroidectomy arms will be checked for superior laryngeal nerve function the day following operation and six months later.

Eligibility criteria:
inclusion criteria: * patients having thyroidectomy exclusion criteria: * previous neck surgery * thyroid cancers * history of superior or inferior laryngeal nerve paralysis * history of neck irradiation * pregnant or lactating women

Keywords: thyroidectomy ultrasonic dissector harmonic focus device superior laryngeal nerve
operation korsband

Conditions: Anterior Cruciate Ligament Injuries

Summary: this study aims to investigate if a detailed and comprehensive survey can identify, explain and prevent the risk factors for acl injury. a a new questionnaire has been developed with questions to young athletes who have suffered an anterior cruciate ligament injury. the questionnaire is more detailed and provide more information about how the anterior cruciate ligament injury occurred compared with the questionnaires currently available in the literature. this careful documentation will provide new knowledge and might be used to identify, explain and prevent risk factors that cause young athletes to suffer an anterior cruciate ligament injury.

participants will be prospectively recruited at their first physiotherapist clinical session. on this occasion, participants will be asked to fill in a questionnaire regarding injury situation, game or training, sex, age, sport affiliation, level of sport, other aspects of sport such as participation in several teams and junior versus senior games/training. in addition, questions regarding previous injury will also be documented.

Eligibility criteria:
inclusion criteria: * athlete * defined acl injury exclusion criteria: * non athletes * younger than 12 years
study of isb 1302 (cd3 bispecific ab) in her2-positive metastatic breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine the safety profile, maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of single agent isb1302 in subjects with her2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.

to determine the safety profile, maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of single agent isb 1302 in subjects with her2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.

Eligibility criteria:
inclusion criteria: * females with her2-positive \[ihc 2 +, with fish confirmation\] or 3+ \[ihc or fish\] metastatic breast cancer that has progressed on last therapy. no more than 4 lines of therapy in metastatic setting (of which no more than 2 lines should be anti-her2 antibody-based therapy). * measurable disease, defined as per recist v1.1. * eastern cooperative oncology group (ecog ) performance-status score of 2 or less * adequate bone marrow, renal, and liver function. * recovered from any previous surgery and no history of major surgery within the last 28 days prior to start of study drug * must be willing to undergo pre-treatment and on-treatment biopsies in part 1 and part 2. exclusion criteria: * any suspected or proven immunocompromised state, or infections, such as history of positive human immunodeficiency virus (hiv), known active or chronic hepatitis b virus (hbv) or hepatitis c virus (hcv). * any history or evidence of clinically significant cardiovascular disease. * evidence of clinically significant cardiovascular and respiratory conditions * previous antineoplastic treatment with immune checkpoint regulator or comparable immunotherapy within 8 weeks of starting study drug. * chemotherapy, radiotherapy, molecular-targeted therapy, or biological therapies (including her2-directed therapies) within 4 weeks of starting study drug * hormone therapy within 2 weeks of starting study medications. * diagnosed with another malignancy that requires active therapy * brain metastases that require directed therapy. * has not recovered from any therapy related toxicities from previous treatments. * use of any investigational drug within 4 weeks from the start of study drug. * any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results.

Keywords: breast cancer gbr 1302 her2 her2 x cd3 bispecific antibody isb 1302 (cd3 bispecific ab) in her2-positive metastatic breast cancer
effectiveness of high intensity electromagnetic therapy and pelvic floor exercises in women with urinary incontinence

Conditions: Urinary Incontinence

Summary: the aim of this study is to evaluate the effect of pelvic floor exercises and high intensity electromagnetic therapy on pelvic floor muscle function, quality of life and urinary parameters in women with stress urinary incontinence. the individuals to be included in the study will be selected from women with stress urinary incontinence who receive follow-up from medipol acıbadem hospital. women who meet the inclusion criteria will be explained the details of the study by the responsible researcher and an informed consent form will be presented. the study is planned as two groups: group 1: pelvic floor muscle training (pbst) group. group 2: pelvic floor muscle training and high intensity functional electromagnetic stimulation (hifem) treatment group. envelope opening method will be used for randomisation of the participants into two groups. they will be included in the first or second group according to the number in the envelope they choose. each participant will be given a baseline assessment. participants in both groups will then receive ptke treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists. participants in 2 groups will also receive hifem treatment for 6 weeks, 2 days a week for 28 minutes. the evaluations will be repeated at the end of the treatment. research outcome measures: demographic and clinical characteristics international incontinence consultation questionnaire-short form urogenital distress inventory (udi-6) quality of life king health survey muscle function emg-biofeedback


Eligibility criteria:
inclusion criteria: * diagnosed as stress urinary incontinence by a physician, * between the ages of 20-65, * has not had recurrent vaginitis infection, * women with no active urinary tract infection or more than 3 urinary tract infections in the last 1 year will be included in the study. exclusion criteria: * history of cardiac implant or untreated cardiac arrhythmia, * the presence of a metal implant, * vaginal and pelvic surgery within the last 6 months, * gave birth within the last 12 weeks and had a history of miscarriage within 6 weeks, * a recent surgical procedure, * any concurrent ui treatment, * with renal and hepatic insufficiency, * neurological or neuromuscular disease * it will be excluded in case of any contraindication listed in the investigational device manual.

Keywords: electromagnetic stimulation urinary incontinence pelvic floor muscle training
a study of the efficacy and safety of topiramate in the prevention of migraine

Conditions: Migraine; Common Migraine; Classic Migraine; Headache

Summary: the purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams\[mg\], 100mg, and 200mg per day) compared with placebo in the prevention of migraine. the study will also assess the dose response relationship and the efficacy of treatment with topiramate versus placebo on health-related quality of life.

this is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of three different doses of topiramate (50mg, 100mg, and 200mg daily) in migraine prophylaxis. the study consists of five phases: baseline (determination of whether patients meet the eligibility criteria and tapering of any migraine medication patients are already taking), double-blind (patients receive either 50 milligrams\[mg\], 100mg, 200mg of topiramate, or placebo), blinded transition phase (doses of study medication are adjusted over 7 weeks in preparation for the open-label extension phase), open-label extension phase (patients continue the study medication in open-label manner for up to 6 months; doses are adjusted to maximize effectiveness and minimize side effects), taper/exit phase (study medication is slowly discontinued over 2 weeks). the primary study hypothesis is that one or more of the three doses of topiramate (50, 100, 200 mg/day) will be superior to placebo in the prophylaxis of migraine based on the change in monthly (28 day) migraine period rate from the prospective baseline period to the double-blind phase. topiramate tablets (50milligrams \[mg\], 100mg, 200mg, or placebo) taken by mouth as twice-daily regimen during the 26-week double-blind phase. doses are adjusted and continued during the 6 month open-label extension phase after which they are tapered over 2 weeks.

Eligibility criteria:
inclusion criteria: * medical history consistent with migraine with or without aura according to the international headache society (ihs) for at least 6 months prior to the study * between 3 to 12 migraine periods and no greater than 15 headache days (migraine and non-migraine) per month during the baseline phase * no clinically significant abnormalities on neurological exams, electrocardiogram (ecg) or clinical laboratory test results at baseline * female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test) exclusion criteria: * patients with headaches other than migraine * patients with episodic tension or sinus headaches * onset of migraine after age of 50 years * patients who have failed more than two adequate regimens for migraine prophylaxis * patients who overuse pain medications or certain other medications

Keywords: migraine common migraine classic migraine headache topiramate prophylaxis prevention
quick recognition of aortic dissection

Conditions: Aortic Dissection

Summary: this is an observational study that establishes a cohort of patients with high risk chest pain who have been identified by cta for aortic dissection. we then used this cohort to validate the accuracy of identifying aortic dissection based on extremity oximetry and doppler waveforms.


Eligibility criteria:
inclusion criteria: * high risk chest pain with cta exclusion criteria: * shock * coma * severe peripheral vascular diseases
bronchial injury caused by bronchial cuff

Conditions: Bronchial Hemorrhage

Summary: double lumen endotracheal tubes (dlt) are wildly used to maintain independent lung ventilation during thoracic surgery. our aim is to assess whether the dlt bronchial cuff inflated or not is associated with tube displacement and bronchial mucosal injury while changing position.

experiment group: before changing from supine position to lateral position, inflate air into the bronchial cuff of double lumen endotracheal tube (dlt) and adjust cuff pressure to 25-30 mmhg. control group: do not inflate air into the bronchial cuff before changing position. main result: degree of left bronchial mucosal injury. secondary result: displacement of double lumen endotracheal tube after changing position. all patients receive general anesthesia and are intubated with left dlt in the supine position. the fiberoptic bronchoscope is used to check the position via tracheal lumen of dlt. the bronchial lumen is placed at the left bronchus and the edge of bronchial cuff is visible by fiberscope. before changing position, the bronchial cuff of experiment group is inflated with air and adjusted cuff pressure to 25-30 mmhg. both groups of patient's neck are fixed by neck collar in order to prevent displacement of dlt by neck rotation. after changing into lateral position, the assistant inflates 2 ml of into the bronchial cuff of control group and adjust cuff pressure to 25-30 mmhg. the investigator, blinded to the tube assignments, uses the fiberoptic bronchoscope to check position of the tube again via tracheal lumen of dlt and record the distance of displacement. at the end of the surgery, both lumens of dlt are sucked and bronchial cuffs are deflated. after pulling out 3 cm of the dlt, the patient is changed into supine position and the fiberoptic bronchoscope is used to check the degree of bronchial injury.

Eligibility criteria:
inclusion criteria: * patients receive elective thoracoscopic wedge resection in the lateral position and are intubated with left side double lumen endotracheal tube. exclusion criteria: * asa status \> iii, coagulopathy, known airway damage, difficult intubation, tracheostomy, double lumen endotracheal tube is displaced during operation which interferes one lung ventilation and needs to be adjusted.
comparative effectiveness clinical trial of mst compared to ect in major depressive disorder

Conditions: Major Depressive Disorder

Summary: this study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (mst) to ect in patients with major depressive disorder (mdd).

magnetic seizure therapy (mst) has previously demonstrated fewer cognitive side effects than ect in randomized trials of efficacy. however, there are currently no real-world effectiveness trials guided by the clinical decision making of the ect psychiatrist as deemed best for the patient. the aims of this study are to: (1) evaluate the comparative effectiveness of mst versus ect in patients with mdd, and (2) compare the cognitive adverse effects of mst and ect, (3) explore changes in spect that is associated with mst treatment and treatment response. patients will be clinically assigned to either ect (n=30) or hd-mst (n=30) twice a week. efficacy will be primarily assessed by the hamilton depression rating scale-21 (hamd-21); primary cognitive side effects were assessed by time to reorientation (tro) and secondarily cognitive battery. brain spect will be done for patients before and after mst.

Eligibility criteria:
inclusion criteria: 1. ability to consent 2. clinically indicated for seizure therapy 3. patients with mdd who had either never received antidepressant treatment or had discontinued antidepressants by their own choice for at least six weeks prior to enrollment (as commonly done in routine clinical care in this jurisdiction due to more negative views of psychotropics) 4. 18-65 years of age. exclusion criteria: 1. dementia, 2. delirium 3. history of significant head trauma 4. neurological disorders (e.g., epilepsy, stroke, multiple sclerosis) 5. substance dependence 6. active comorbidity with another psychiatric disorder 7. patients who had previously received ect or tms 8. current unstable or serious medical illness (e.g., myocardial infarction) 9. pregnancy 10. presence of implanted electronic devices (e.g., cardiac pacemaker, cochlear implants) 11. inability to participate in testing

Keywords: mst ect mdd depression major depressive disorder magnetic seizure therapy electroconvulsive therapy treatment resistant depression (trd)